- Home
- WIA vs SLN Comparison
WIA vs SLN Comparison
Compare WIA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- SLN
- Stock Information
- Founded
- WIA 2003
- SLN 1994
- Country
- WIA United States
- SLN United Kingdom
- Employees
- WIA N/A
- SLN N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- SLN Health Care
- Exchange
- WIA Nasdaq
- SLN Nasdaq
- Market Cap
- WIA 196.4M
- SLN 227.2M
- IPO Year
- WIA N/A
- SLN N/A
- Fundamental
- Price
- WIA $8.41
- SLN $4.77
- Analyst Decision
- WIA
- SLN Buy
- Analyst Count
- WIA 0
- SLN 5
- Target Price
- WIA N/A
- SLN $32.60
- AVG Volume (30 Days)
- WIA 39.2K
- SLN 60.1K
- Earning Date
- WIA 01-01-0001
- SLN 08-07-2025
- Dividend Yield
- WIA 12.29%
- SLN N/A
- EPS Growth
- WIA N/A
- SLN N/A
- EPS
- WIA N/A
- SLN N/A
- Revenue
- WIA N/A
- SLN $27,169,000.00
- Revenue This Year
- WIA N/A
- SLN N/A
- Revenue Next Year
- WIA N/A
- SLN N/A
- P/E Ratio
- WIA N/A
- SLN N/A
- Revenue Growth
- WIA N/A
- SLN 22.28
- 52 Week Low
- WIA $7.56
- SLN $1.97
- 52 Week High
- WIA $8.91
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- WIA 56.05
- SLN 34.24
- Support Level
- WIA $8.29
- SLN $4.91
- Resistance Level
- WIA $8.41
- SLN $5.29
- Average True Range (ATR)
- WIA 0.05
- SLN 0.44
- MACD
- WIA 0.01
- SLN -0.06
- Stochastic Oscillator
- WIA 61.90
- SLN 0.00
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.